A. Militello

Proposed clinical management of pregnancies after combined screening for pre‐eclampsia at 35–37 weeks' gestation

D. Wright, K. Nicolaides, K. Nicolaides, 2017, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients.

M. Reni, S. Cascinu, G. Orsi, 2022, Cancer treatment reviews.

Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.

C. Porta, M. Milella, S. Buti, 2019, Clinical genitourinary cancer.

Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey

M. Reni, S. Bozzarelli, M. Di Marco, 2021, ESMO open.

Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review

A. Musolino, B. Bortesi, M. Michiara, 2019, Front. Oncol..

Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)

E. Vasile, M. Reni, G. Tortora, 2022, British Journal of Cancer.

Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma.

M. Reni, M. Falconi, S. Cascinu, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes

M. Reni, G. Tortora, S. Bozzarelli, 2023, Cancer Chemotherapy and Pharmacology.